Ticker

Analyst Price Targets — VYNE

Page 1 • Showing up to 10
DateAnalystFirmTargetPrice @ PostSourceHeadline
June 14, 2024 7:58 amJoseph PantginisH.C. Wainwright$5.75$2.11StreetInsider H.C. Wainwright Reiterates Buy Rating on VYNE Therapeutics (VYNE)

Latest News for VYNE

Short Interest in VYNE Therapeutics Inc. (NASDAQ:VYNE) Decreases By 35.7%

VYNE Therapeutics Inc. (NASDAQ: VYNE - Get Free Report) was the recipient of a significant decrease in short interest in the month of March. As of March 31st, there was short interest totaling 121,535 shares, a decrease of 35.7% from the March 15th total of 188,899 shares. Based on an average daily trading volume, of 214,716

Defense World • Apr 15, 2026
Contrasting Vivani Medical (NASDAQ:VANI) & VYNE Therapeutics (NASDAQ:VYNE)

VYNE Therapeutics (NASDAQ: VYNE - Get Free Report) and Vivani Medical (NASDAQ: VANI - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk. Volatility and Risk VYNE Therapeutics has a

Defense World • Mar 15, 2026
VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Down 61.3% in February

VYNE Therapeutics Inc. (NASDAQ: VYNE - Get Free Report) was the target of a large drop in short interest in February. As of February 27th, there was short interest totaling 212,702 shares, a drop of 61.3% from the February 12th total of 549,047 shares. Based on an average daily trading volume, of 435,988 shares, the short-interest

Defense World • Mar 11, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for VYNE.

No House trades found for VYNE.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top